A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen
Okudera, K.; Takanashi, S.; Hayashi, A.; Morimoto, T.; Nakamura, K.; Mikuniya, M.; Dempoya, J.; Okumura, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(11): 1889-1891
2009
ISSN/ISBN: 0385-0684 PMID: 19920394 Document Number: 634534
The patient was a 36-year-old male. He visited our department in February 2004 as a prior chest X-ray revealed multiple nodular shadows. After further examinations, he was diagnosed with stage IV adenocarcinoma of the lung. As treatment, 5 courses of carboplatin (CBDCA)+docetaxel (DOC), 3 courses of CBDCA+gemcitabine (GEM), 6 weeks of gefitinib, and 3 courses of GEM were administered. However, the tumor progressed, and S-1 (120 mg/day, 2 weeks on, 1 week off) was administered as the sixth regimen from May 2006. No severe side effects were observed, and an antitumor action was achieved over a relatively long period. Therefore, it was suggested that a single administration of S-1 for non-small cell lung cancer, which had been treated with other multiple regimens, is safe, and long-term control of the disease can be expected.